Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM355
- Development stage
- Phase 2
- Lead developer
- InnoCare Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CM355 is a novel bispecific monoclonal antibody and T-cell engager that targets both the tumor-associated antigen CD20 on B cells and the CD3 antigen on T cells. By binding to these two targets, CM355 redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC). It is being developed for the treatment of CD20-positive B-cell malignancies, including non-Hodgkin lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The drug is being developed by a joint venture between InnoCare Pharma and Keymed Biosciences[1][2][3][4][5][6].
- Other names
- anti-CD20/anti-CD3 bispecific antibody CM355CD20xCD3 bispecific antibodyCD-20xCD3 bispecific antibodyCD 20xCD3 bispecific antibody
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CM355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM355.